Dapiglutide for the Treatment of Obesity

NCT ID: NCT05788601

Last Updated: 2024-12-05

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-04-27
• Study Completion Date: 2025-08-15

Brief Summary

This study is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, parallel-group, single-centre clinical trial investigating the body weight loss potential of dapiglutide, a dual GLP-1R/GLP-2R agonist, administered subcutaneously once weekly. The study will investigate the efficacy of once-weekly subcutaneously administered of 4 mg and 6 mg dapiglutide versus placebo in 54 obese individuals (BMI >30 kg/m2) during a 12-week treatment period.

Detailed Description

In total, 54 obese participants with a body mass index (BMI) of ≥ 30 kg/m² are randomised to either treatment with the investigational medicinal product (IMP), being either dapiglutide 4 mg, dapiglutide 6 mg, or placebo for 12 weeks. To ensure blinding, the placebo arm is split between 4 mg and 6 mg placebo, making the randomisation sequence 2:2:1:1. The trial encompasses a 3-week screening period containing a screening visit (V1) to assess eligibility, followed by a randomisation visit (V2) and subsequently a 12-week treatment period concluded with a 4-week follow-up period. The IMP is subcutaneously administered in the abdomen once weekly from week 0 (V2) until week 12 (V14). The IMP is initiated at 2 mg once-weekly and up-titrated every third week with 2 mg until the respective trial doses are reached in each arm. Hereafter, the participants are kept at the dose level for the remainder of the trial (from week 3 and week 6 for the 4 mg and 6 mg doses, respectively). To reduce dropout in cases of low tolerability of the IMP, the investigator can postpone up-titration or down-titrate if judged necessary for participant retention or safety. The trial schedule will consist of five on-site visits, including screening, randomisation and a safety follow-up visit (four weeks after end of treatment (EOT)), in addition to a minimum of 10 telephone consultations. Therefore, the maximum trial duration is 16 weeks. For exploratory purposes, participants are invited to participate in a gastroduodenoscopy sub-study obtaining gastric and duodenal biopsies before and after treatment with IMP. A maximum of 7 participants from each treatment arm (total n=21) participate in this sub-study.

Conditions

Obesity; Inflammation

Keywords

Gut barrier function

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Placebo (4 mg and 6 mg)

Abdominal s.c. self-administration of placebo content once weekly for 12 weeks. To ensure double-blinding, the placebo arm is divided into a 4-mg and 6-mg arm. But both placebo arms are pooled during data analysis.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

4 mg dapiglutide

Abdominal s.c. self-administration of 4 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks until the remaining nine weeks of treatment (12 weeks in total)

Group Type: ACTIVE_COMPARATOR

Dapiglutide

Intervention Type: DRUG

GLP-1/GLP-2 receptor agonism

6 mg dapiglutide

Abdominal s.c. self-administration of 6 mg dapiglutide once weekly initiated at 2 mg and up-titrated after three weeks to 4 mg and again to 6 mg after six weeks until the remaining six weeks of treatment (12 weeks in total)

Group Type: ACTIVE_COMPARATOR

Dapiglutide

Intervention Type: DRUG

GLP-1/GLP-2 receptor agonism

Interventions

Dapiglutide

GLP-1/GLP-2 receptor agonism

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Other Intervention Names

ZP7570

Eligibility Criteria

Inclusion Criteria

• Age 18-75 years
• BMI ≥ 30 kg/m²
• History of at least one attempt to lose body weight

Exclusion Criteria

• A self-reported change in body weight ≥ 5% within the last 90 days prior to the screening visit
• Treatment with any therapy, including endoscopic procedures and/or medication (e.g. liraglutide, bupropion/naltrexone and orlistat), intended for weight management within 90 days prior to screening
• Previous, current, or planned (during the trial period) obesity treatment with surgery or a weight loss device < 1 year prior to screening
• Glycated haemoglobin (HbA1c) ≥ 48 mmol/mol
• History of type 1 diabetes or type 2 diabetes
• Treatment with glucose-lowering agents within 90 days prior to screening
• Compromised kidney function (estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2) at screening
• Known liver disease (except for non-alcoholic fatty liver disease) and/or elevated plasma alanine aminotransferase (ALT) > three times the upper limit of normal at screening
• History of acute and/or chronic pancreatitis
• History and/or family history of medullary carcinoma and/or multiple endocrine neoplasia syndrome
• Inflammatory bowel disease
• Any history of colon cancer or intestinal polyps
• Any history of intestinal stenosis
• History of any other cancers (except margin-free resected cutaneous basal or squamous cell carcinoma or adequately treated in situ cervical cancer) unless disease-free state for at least five years
• Uncontrolled thyroid disease as per discretion of the investigators
• Any of the following: myocardial infarction, stroke, hospitalisation for angina and transient ischaemic attack within the last 60 days prior to screening
• Class IV heart failure according to the New York Heart Association
• Any concomitant disease or treatment that, at the discretion of the investigators, might jeopardise the participant's safety during the trial
• Alcohol/drug abuse as per discretion of the investigators
• Known or suspected hypersensitivity to the trial product or related products
• Previous treatment with the trial product
• Administration of an investigational drug within 90 days prior to screening
• Simultaneous participation in any other clinical intervention trial
• Mental incapacity or language barriers that preclude adequate understanding or cooperation, or unwillingness to comply with trial requirements
• Use of GLP-1RA, GLP-2RA, dipeptidyl peptidase 4 (DPP) inhibitors, human growth hormone, somatostatin, or analogues thereof, within three months prior to screening
• Known radiation enteritis or significant villous atrophy, e.g., due to active coeliac disease or inflammatory bowel disease
• Regarding fertile men and women:

• Women who are pregnant, breastfeeding, intend to become pregnant or are of childbearing potential will not be included in the study
• Sterilised or postmenopausal women (> 12 months amenorrhoea or females ≥ 60 years of age) can be included
• The following contraceptive methods are considered adequate for study enrolment of male participants: Surgically sterilised or willing to refrain from sexual intercourse from screening and until completion of the follow-up visit, or, if sexually active, condom usage and partner-practised contraception during the trial, i.e., from screening to the last visit

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Zealand Pharma

INDUSTRY

Sponsor Role: collaborator

University Hospital, Gentofte, Copenhagen

OTHER

Sponsor Role: lead

Responsible Party

Filip Krag Knop

Principal Investigator, Clinical Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Filip K Knop, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Center for Clinical Metabolic Research at Gentofte Hospital

Locations

Center for Clinical Metabolic Research, Herlev-Gentofte Hospital

Hellerup, , Denmark

Countries

Denmark

Provided Documents

Document Type: Study Protocol

View Document

Other Identifiers

2022-501649-54-00

Identifier Type: OTHER

Identifier Source: secondary_id

The 'DREAM' trial

Identifier Type: -

Identifier Source: org_study_id